Search results for "METHOTREXATE"

showing 10 items of 111 documents

Etoposide Treatment in Recurrent Medulloblastoma

1994

Five consecutive patients with recurrent medulloblastoma received etoposide 120 mg/m2 for 5 to 7 days at 2 to 4-week intervals. Three patients with neuroaxis dissemination received additional intrathecal chemotherapy with methotrexate, cytosine arabinoside and prednisone. Toxicity consisted of alopecia and mild neutropenia. Complete response was registered in two patients, partial response in one. Median survival was 19 months with the 3 responders living 6, 30 and 60+ months. Etoposide seems to be an active agent in medulloblastoma.

AdultMalemedicine.medical_specialtymedicine.medical_treatmentNeutropeniaGastroenterologyRecurrencePrednisoneInternal medicinemedicineHumansSpinal Cord NeoplasmsNeoplasm MetastasisChildEtoposideEtoposideMedulloblastomaChemotherapyBrain Neoplasmsbusiness.industryGeneral MedicineRecurrent MedulloblastomaPrognosismedicine.diseaseFrontal LobeSurgeryTreatment OutcomeChild PreschoolPediatrics Perinatology and Child HealthToxicityFemaleMethotrexateNeurology (clinical)Tomography X-Ray ComputedbusinessMedulloblastomamedicine.drugNeuropediatrics
researchProduct

Long term structural effects of combination therapy in patients with early rheumatoid arthritis: five year follow up of a prospective double blind co…

2003

Objective: To evaluate whether early combined therapy with methotrexate (MTX) and sulfasalazine (SSZ) during the first year in early rheumatoid arthritis (RA) induces long term beneficial effects, compared with monotherapy, when the further treatment strategy is a free choice. Methods: Study design: five year multicentre prospective longitudinal trial. Participants: 146/205 patients with RA previously included in a one year prospective randomised trial comparing the effects of treatment with MTX, SSZ, or a combination of both. Criteria for inclusion: patients with early RA (⩽1 year duration). Follow up: between the end of years 1 and 5, patients were followed up and treated by their own rhe…

AdultMalemusculoskeletal diseasesmedicine.medical_specialtyConcise ReportCombination therapymedicine.medical_treatmentImmunologyArthritisSeverity of Illness IndexGeneral Biochemistry Genetics and Molecular Biologylaw.inventionArthritis RheumatoidDouble-Blind MethodRheumatologyRandomized controlled triallawSulfasalazineInternal medicinemedicineHumansImmunology and AllergyProspective StudiesDisease-modifying antirheumatic drugskin and connective tissue diseasesProspective cohort studyAgedAnalysis of Variancebusiness.industryMiddle Agedmedicine.diseaseSurgerySulfasalazineClinical trialMethotrexateTreatment OutcomeAntirheumatic AgentsRheumatoid arthritisDrug Therapy CombinationFemalebusinessFollow-Up Studiesmedicine.drugAnnals of the Rheumatic Diseases
researchProduct

Metronomic chemotherapy for advanced breast cancer patients in the real world practice: Final results of the VICTOR-6 study

2019

Abstract Metronomic chemotherapy (mCHT) refers to the minimum biologically effective dose of a chemotherapy agent given as a continuous dosing regimen, with no prolonged drug-free breaks, that leads to antitumor activity. Aim of the present study is to describe the use of mCHT in a retrospective cohort of metastatic breast cancer (MBC) patients in order to collect data regarding the different types and regimens of drugs employed, their efficacy and safety. Between January 2011 and December 2016, data of 584 metastatic breast cancer patients treated with mCHT were collected. The use of VRL-based regimens increased during the time of observation (2011: 16.8% - 2016: 29.8%), as well as CTX-bas…

AdultOncologymedicine.medical_specialtyCyclophosphamideSettore MED/06 - Oncologia MedicaAntineoplastic AgentsBreast NeoplasmsVinorelbineDrug Administration ScheduleAntineoplastic AgentEfficacyCapecitabine03 medical and health sciencesBreast cancer0302 clinical medicineBreast cancerRetrospective StudieInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumans030212 general & internal medicineProgression-free survivalCyclophosphamideRetrospective StudiesAgedAged 80 and overAntineoplastic Combined Chemotherapy Protocolbusiness.industryMetronomic chemotherapyVinorelbineGeneral MedicineMiddle Agedmedicine.diseaseMetastatic breast cancerMetronomic ChemotherapySurvival RateMethotrexateTreatment Outcome030220 oncology & carcinogenesisMED/06 - ONCOLOGIA MEDICAFemaleSurgerybusinessBreast NeoplasmHumanmedicine.drugThe Breast
researchProduct

Combined use of uterine artery embolization and local methotrexate injection in interstitial ectopic pregnancies with poor prognosis.

2009

Objective To report three cases of interstitial pregnancies treated successfully by combining uterine artery embolization (UAE) and ultrasound-guided local administration of methotrexate (MTX); and to assess the effect of UAE on ovarian reserve by prospectively measuring serum antimullerian hormone (AMH) levels. Design Case report. Setting Departments of obstetrics and gynecology and radiology of a university hospital. Patient(s) Three patients with interstitial pregnancy. Treatment with multiple IM injections of MTX had failed in cases 1 and 3. Case 2 presented high initial serum β-hCG levels (93,563 mIU/mL), suggesting the presence of a substantial amount of trophoblastic tissue. Interven…

Adultendocrine systemPoor prognosismedicine.medical_specialtymedicine.medical_treatmentCombined useUterine artery embolizationObstetrics and gynaecologyPregnancymedicineHumansOvarian reservePregnancybusiness.industryObstetricsObstetrics and GynecologyUterine Artery Embolizationmedicine.diseasePrognosisCombined Modality TherapyPregnancy EctopicMethotrexateReproductive MedicineMethotrexateInterstitial pregnancyFemalebusinessmedicine.drugFertility and sterility
researchProduct

Familial adenomatosis polyposis-related desmoid tumours treated with low-dose chemotherapy: Results from an international, multi-institutional, retro…

2019

[Introduction] Desmoid tumour (DT) is a locally aggressive fibroblastic proliferative disease representing the most common extraintestinal manifestation of familial adenomatosis polyposis (FAP). As data on the activity of chemotherapy in these patients are limited, we examined the outcomes of patients treated with low-dose methotrexate (MTX)+vinca alkaloids (vinorelbine or vinblastine).

Adultfamilial adenomatosis polyposiCancer Researchmedicine.medical_specialtyVincaAdolescentVinca alkaloidsdesmoidmedicine.medical_treatmentPopulationVinorelbinechemotherapyGastroenterologymethotrexatevinca alkaloidsYoung Adultchemotherapy; desmoid; familial adenomatosis polyposis; methotrexate; vinca alkaloidsLow-dose chemotherapyInternal medicinemedicineHumansChemotherapyChildeducationDesmoidSurvival analysisRetrospective StudiesChemotherapyeducation.field_of_studybiologybusiness.industryFamilial adenomatosis polyposisbiology.organism_classificationmedicine.diseasefamilial adenomatosis polyposisMethotrexateAdenomatous Polyposis ColiOncologyFemaleSarcomabusinessProgressive diseasemedicine.drug
researchProduct

Modulation of oestrogen excretion profiles by adjuvant chemotherapy in pre- and postmenopausal breast cancer.

1985

Modulation of steroid status by conventional chemotherapy was studied in 31 breast cancer patients receiving CMF and in 31 age-matched breast cancer patients without any therapy, taken as controls. This was achieved through the study of oestrogen excretion profiles using previously identified parameters and referring not only to classical but also to the “other”, namely catechol and unusual, oestrogen metabolites. After CMF treatment the premenopausal patients exhibit a modified excretion pattern, mainly concerning a marked and significant reduction of classical oestrogens, as shown by pattern indices. Because there is evidence that oestriol metabolism is not markedly affected by CMF treatm…

Adultmedicine.medical_specialtyTime FactorschlormethineAdjuvant chemotherapymedicine.medical_treatmentBreast NeoplasmsBiochemistryestriolGas Chromatography-Mass SpectrometrySteroidExcretionEndocrinologyBreast cancerInternal medicineestradiolAntineoplastic Combined Chemotherapy ProtocolsmedicineestrogenHumansStage (cooking)CyclophosphamideChromatography High Pressure LiquidAgedbusiness.industryEstrogensMetabolismMiddle Agedmedicine.diseaseestroneEstrogens CatecholEndocrinologyMethotrexateMetabolic rateAdrenal CortexFemaleFluorouracilMenopausebusinessAfter treatmentJournal of steroid biochemistry
researchProduct

Unruptured tubal pregnancy: local low-dose therapy with methotrexate under transvaginal ultrasonographic guidance.

1996

Thirty patients with unruptured ectopic pregnancy (4-10 weeks' gestation) were treated locally with methotrexate (MTX) under sonographic guidance. The transvaginal puncture was performed under analgesic sedation using an automatic puncturing device. Local MTX therapy was successful in 25 patients (83.3%). Eighteen of these patients had received a single MTX instillation with a total dose of 10 mg, 7 patients had received a second instillation with 10 mg because of plateauing hCG levels after the first instillation. In 5 patients MTX therapy was unsuccessful. Surgical intervention was necessary within 4 h to 15 days after MTX treatment, due to severe tubal bleeding (n = 1) or the development…

Adultmedicine.medical_specialtymedicine.drug_classAntimetaboliteChorionic Gonadotropinchemistry.chemical_compoundRoute of administrationPregnancyUnruptured tubal pregnancymedicineHumansUltrasonographyEctopic pregnancybusiness.industryLow doseObstetrics and Gynecologymedicine.diseaseSurgeryTrophoblastsMethotrexateReproductive MedicinechemistryAntifolateGestationMethotrexateFemalePregnancy Tubalbusinessmedicine.drugGynecologic and obstetric investigation
researchProduct

Managing Adult-onset Still's disease: The effectiveness of high-dosage of corticosteroids as first-line treatment in inducing the clinical remission.…

2019

Abstract To assess the effectiveness of the treatment with high dosage of corticosteroids (CCSs), as first-line therapy, in inducing remission in naïve Adult-onset Still's disease (AOSD) patients compared with low dosage of CCSs, after 6 months. To further evaluate the rate of patients maintaining the remission and the rate of CCSs discontinuation, after additional 12 months of follow-up. A retrospective evaluation of patients prospectively followed was designed to compare the rate of clinical remission in naïve AOSD patients treated with high dosages of CCSs (0.8–1 mg/kg/day of prednisone-equivalent) or low dosage of CCSs (0.2–0.3 mg/kg/day of prednisone-equivalent), after 6 months. An add…

Adult-OnsetMalePediatricsAdult-onset Still's diseaseDiseaseAdrenal Cortex Hormonecorticosteroids0302 clinical medicinemonocyclic patternAdrenal Cortex HormonesRetrospective StudieMedicine030212 general & internal medicineProspective StudiesProspective cohort studyRemission InductionDisease ManagementGeneral MedicineMiddle AgedTreatment OutcomeHigh dosage030220 oncology & carcinogenesisFemaleDrugStill's Disease Adult-OnsetResearch ArticleHumanAdultcorticosteroidmedicine.medical_specialtyLow dosageObservational StudyAdult-onset Still's diseaseFollow-Up StudieDose-Response Relationship03 medical and health sciencesremissionAdult-onset Still's disease; corticosteroids; first-line therapy; monocyclic pattern; remission; Adrenal Cortex Hormones; Adult; Disease Management; Dose-Response Relationship Drug; Female; Follow-Up Studies; Humans; Male; Methotrexate; Middle Aged; Prospective Studies; Remission Induction; Retrospective Studies; Still's Disease Adult-Onset; Treatment Outcomefirst-line therapyHumansRetrospective StudiesDose-Response Relationship Drugbusiness.industry6900Retrospective cohort studyStill's DiseaseFirst line treatmentSettore MED/16 - ReumatologiaProspective StudieMethotrexateObservational studybusinessFollow-Up Studies
researchProduct

Global treatment patterns and outcomes among patients with recurrent and/or metastatic head and neck squamous cell carcinoma: Results of the GLANCE H…

2020

Abstract Objectives Given a lack of universally-accepted standard-of-care treatment for patients with recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC), study objectives were to assess treatment utilization and survival outcomes for R/M HNSCC in the real-world setting. Materials and methods A multi-site retrospective chart review was conducted in Europe (Germany, United Kingdom, Italy, Spain), Asia Pacific (Australia, South Korea, Taiwan), and Latin/North America (Brazil and Canada) to identify patients who initiated first-line systemic therapy for R/M HNSCC between January 2011 and December 2013. Patients were followed through December 2015 to collect clinical characte…

Bridged-Ring CompoundsMaleCanadaCancer Researchmedicine.medical_specialtymedicine.medical_treatmentTaiwanMedizinCetuximabPlatinum CompoundsKaplan-Meier EstimateSystemic therapy03 medical and health sciences0302 clinical medicineInternal medicineAntineoplastic Combined Chemotherapy ProtocolsRepublic of KoreaConfidence IntervalsmedicineHumans030223 otorhinolaryngologySurvival analysisAgedRetrospective StudiesChemotherapyCetuximabSquamous Cell Carcinoma of Head and Neckbusiness.industryHead and neck cancerAustraliaMiddle Agedmedicine.diseaseHead and neck squamous-cell carcinomaConfidence intervalEuropeRegimenMethotrexateTreatment OutcomeOncologyHead and Neck Neoplasms030220 oncology & carcinogenesisFemaleTaxoidsFluorouracilNeoplasm Recurrence LocalOral SurgerybusinessBrazilmedicine.drugOral Oncology
researchProduct

Medical management of Crohn's disease

2011

The medical approach to Crohn's disease has been modified in recent years thanks to the introduction of new therapies, like biologics. Also, well-designed studies and systematic reviews have allowed better evaluation of the role of old drugs like steroids and immunosuppressors. This review aims to evaluate the recent evidence on the medical approach to Crohn's disease in the different settings of the disease.Randomized controlled trials and meta-analyses were included in the review. The research on all the studies discussed was based on the Cochrane Library, Medline and Embase, using the following medical subject headings: Crohn's disease, clinical trial, therapy, 5-aminosalicylic acid, ste…

Budesonidemedicine.medical_specialtyPathologyAnti-Inflammatory AgentsMEDLINEDiseaseCochrane LibraryManagement of Crohn's diseaselaw.inventionCrohn DiseaseRandomized controlled trialAdrenal Cortex HormoneslawmedicineHumansPharmacology (medical)BudesonideIntensive care medicineBone Marrow TransplantationPharmacologyBiological ProductsTumor Necrosis Factor-alphabusiness.industryRemission InductionGeneral Medicinemedicine.diseaseAnti-Bacterial AgentsIntestinesClinical trialAminosalicylic AcidsMethotrexateTreatment OutcomeSystematic reviewPurinesbusinessImmunosuppressive Agentsmedicine.drugExpert Opinion on Pharmacotherapy
researchProduct